期刊
BRITISH JOURNAL OF CANCER
卷 127, 期 2, 页码 173-184出版社
SPRINGERNATURE
DOI: 10.1038/s41416-022-01768-9
关键词
-
类别
资金
- CPRIT [RP160710/RP170172]
- NSF [PHY-1935762]
- NIH/NCI [R01CA200970, 2R01CA155243]
- Bowes Foundation
- MD Anderson Cancer Center Support Grant [CA016672]
Liquid biopsies have become increasingly important in cancer diagnosis and monitoring. Circulating tumor cells (CTCs), as a robust biomarker, can predict therapy response and disease progression.
Over the past decade, cancer diagnosis has expanded to include liquid biopsies in addition to tissue biopsies. Liquid biopsies can result in earlier and more accurate diagnosis and more effective monitoring of disease progression than tissue biopsies as samples can be collected frequently. Because of these advantages, liquid biopsies are now used extensively in clinical care. Liquid biopsy samples are analysed for circulating tumour cells (CTCs), cell-free DNA, RNA, proteins and exosomes. CTCs originate from the tumour, play crucial roles in metastasis and carry information on tumour heterogeneity. Multiple single-cell omics approaches allow the characterisation of the molecular makeup of CTCs. It has become evident that CTCs are robust biomarkers for predicting therapy response, clinical development of metastasis and disease progression. This review describes CTC biology, molecular heterogeneity within CTCs and the involvement of EMT in CTC dynamics. In addition, we describe the single-cell multi-omics technologies that have provided insights into the molecular features within therapy-resistant and metastasis-prone CTC populations. Functional studies coupled with integrated multi-omics analyses have the potential to identify therapies that can intervene the functions of CTCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据